XHKG
2135
Market cap7mUSD
Feb 13, Last price
0.10HKD
Name
Raily Aesthetic Medicine International Holdings Ltd
Chart & performance
P/E
26.97
P/S
0.27
EPS
0.00
Vol. 1Y
—
Shs. 5Y
10.12%
Rev. 5Y
2.32%
Div Yld LY
—
Div Yld TTM
—
Revenues
185m
-7.44%
Net income
2m
P
CFO
35m
+477.66%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Raily Aesthetic Medicine International Holdings Limited is an investment holding company primarily engaged in providing a comprehensive range of cosmetic medical services. Its operations are structured into three principal segments: Aesthetic Medical Services, Consulting Services, and the distribution of Aesthetic Medical Equipment Products. The company's service offerings include various aesthetic procedures such as: Surgical interventions: encompassing cosmetic surgeries performed on different areas of the face or body. Minimally invasive treatments: largely consisting of aesthetic injection procedures. Aesthetic dermatology: featuring diverse energy-based treatments. Aesthetic dental care: including orthodontic services, dental implants, and teeth whitening. Management consulting: providing specialized advisory services for aesthetic medical practices. Furthermore, Raily trades in medical equipment and sells surgical implants alongside aesthetic medical skincare products. The company manages and operates a network of four private, for-profit aesthetic medical clinics located in China's Zhejiang and Anhui Provinces. It serves a diverse clientele, including individual retail customers and other aesthetic medical institutions. Founded in 2008 and headquartered in Hangzhou, People's Republic of China, Raily Aesthetic Medicine International Holdings Limited operates as a subsidiary of Ruide Consultation Limited.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||